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Abstract
Purpose: A population-based cohort study of soft tissue sarcoma of the extremities (STSE) in Ontario, Canada was conducted
using linked administrative databases.
Methods and materials: Electronic administrative databases were linked from the Ontario Cancer Registry, the Canadian
Institute for Health Information, and Radiation Oncology Research Unit database of radiation therapy (RT) records.
Results: The definitive surgery was amputation for 6.0%, resection for 60.9%, biopsy for 7.5%; the remainder had no surgical
record. Adjuvant RT was administered to 40.2% of cases. Among cases initially treated by surgical resection, 2.0% later
underwent amputation and 9.5% underwent further resection during follow-up. The adjusted odds ratio (OR) for amputa-
tion as definitive surgery was 2.3 (1.19, 4.45) in eastern Ontario relative to Toronto. The likelihood of adjuvant RT among
those not registered at a cancer centre within 3 months of diagnosis was decreased (OR = 0.20 (95% CI (0.13, 0.30)) relative
to those registered. The adjusted relative risk of amputation at any time following diagnosis was 3.48 (95% CI (1.63, 7.46))
among cases not attending a cancer centre. The adjusted relative risk of death was 1.4; 95% CI (1.1, 1.7) among those not
attending a cancer centre.
Conclusions: Cases not seen at a multidisciplinary cancer centre within 3 months following diagnosis of STSE have an
increased relative risk for amputation at any time, and for death due to any cause. Many hypotheses for further study are
suggested by the results of this analysis.
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Introduction
Although  soft  tissue  sarcoma  of  the  extremities
(STSE)  among  adults  comprises less  than  1%  of
incident cancers, the burden of suffering for cases of
STSE is great, because of disfigurement, disability,
and mortality.
Most surgeons and oncologists rarely treat patients
with STSE and do not develop expertise in its diag-
nosis and treatment. Processes for the diagnosis and
treatment of STSE are very complex. There are inter-
national  recommendations  for  the  care  of  STSE
patients that mandate consultation with subspecial-
ized  surgical,  radiation,  and  medical  oncologists,
prior  to  definitive  treatment.1–5  The  Society  for
Surgical Oncology and the National Comprehensive
Cancer  Network  have  published  consensus-based
guidelines on some aspects of the care of STSE.6,7
However,  the  proportion  of  STSE  cases  receiving
such care is unknown. Such care is recommended in
oncology in general,8 and has been associated with
improved outcomes in population-based studies of
other malignancies.9,10
The goal of treatment for STSE is to avoid mutila-
tion and/or disability whenever possible, while offer-
ing each patient the highest possibility of curing the
disease.11–14 In reports of RCTs and institutional case
series, there is evidence that correctly performed treat-
ments directed at  limb preservation, with function
acceptable  to  patients,  are  effective  in appropriate
cases.12,13,15 Procedures must be correctly selected
and performed, for highest likelihood of histopatho-
logically clear resection margins, limb preservation,
and good function.6,16–19
Population-based studies of STSE have indicated
much lower rates of referral to expert services than20 L. Paszat et al.
predicted.2,3,20  Some  biopsies  are  performed
incorrectly,21 and histopathology reporting may be
incorrect or inadequately reported, and expert review
may be omitted. Omission or incorrect selection or
interpretation of diagnostic imaging are common.2
If inexpert surgical procedures are  performed in
the  first  instance,2,6,16–19  there  may  be  a  higher
probability of unsatisfactory surgical resection mar-
gins, with a higher rate of local failure, and a higher
number of surgical procedures performed on STSE.
Clasby et al.2 concluded that best available evidence
for treatment had  not been applied. Inappropriate
surgery had been performed, including unnecessary
amputation. A total of 67.1% of resection specimens
contained  unsatisfactory  resection  margins.  Adju-
vant RT had been omitted despite being indicated
by  the  extent  of  disease.  Clasby  et  al.2  deemed
that overall  only  60%  of  cases  had  been  treated
adequately.
This  paper  presents  a  population-based  cohort
study of STSE in Ontario. The objectives of the study
were: (1) to describe STSE case volumes of hospitals
and cancer centres, in order to express the magnitude
of institutional experience in the treatment of cases of
STSE as a surrogate measure of specialized expertise;
(2) to describe the proportion of cases admitted to
hospitals with the largest experience in the treatment
of cases of STSE and the proportion of cases of STSE
that  attend  a  multidisciplinary cancer centre (as  a
surrogate measure of multidisciplinary care); and (3)
to describe the treatment of newly diagnosed STSE
and clinical outcomes, in relation to institutional case
volume.
Methods
Study design
The study design is a population-based cohort of all
cases of STSE diagnosed in Ontario between 1 January
1987 and 31 December 1996, who were aged 17 and
older at the time of diagnosis. The study is based on
linked electronic administrative health services data-
bases  originally  intended  for  other  purposes:  the
Ontario Cancer Registry (OCR), hospital files from
the  Canadian  Institute  for  Health  Information
(CIHI), and radiotherapy (RT) files from all RT facil-
ities in Ontario, compiled by the Radiation Oncology
Research  Unit  (RORU),  Queen’s  University  at
Kingston, Ontario.
Data sources and variables
The OCR files included the following variables: ICD
diagnosis, ICD-O histology code, diagnosis date, age
at  diagnosis,  Ministry  of  Health  residence  code,
postal code, numeric cancer centre label, and cancer
centre chart number. The OCR ascertains cases on
the basis of data from the following records originally
created for other purposes: (1) registrations at cancer
centres; (2) pathology reports received directly from
acute care hospitals; (3) hospital discharge abstracts
received  from  the  Canadian  Institute  for  Health
Information  (CIHI);  and  (4)  death  certificate
diagnoses.22
Electronic hospital discharge abstracts from CIHI
contain  the  admission  date,  discharge  date,  and
major treatment procedures. The validity and reli-
ability of electronic reports of cancer-directed surgery
has  been  described  by  Holowaty  et  al.23  Surgical
treatment directed at the primary STSE was catego-
rized from the Canadian Classification of Procedures
codes contained in the CIHI files as ‘amputation’,
‘resection’, ‘biopsy’ or ‘other’.
Electronic RT records from all cancer centres in
Ontario were compiled, processed and analyzed by
RORU, which linked these files to the OCR case files.
Only 1% of cancer patients have a record of RT in
original  charts  but  none  in  the  electronic  file.24
Records of adjuvant RT were selected by the codes
describing the anatomic region treated.
These  linked  data  do  not  contain  information
about the stage or grade of STSE at diagnosis, physi-
cian characteristics, the completeness or reliability of
diagnostic imaging or pathology reporting, diagnostic
delay, the use of chemotherapy, or direct histological
or radiological ascertainment of local recurrence and/
or distant metastasis of STSE.
Process of care variables
‘Case volumes of hospitals and cancer centres’
STSE case volumes during the study period were cal-
culated for hospitals of first admission, for hospitals
performing  maximal  surgical  procedures  within  8
months of diagnosis, and for cancer centres, in order
to describe the STSE experience of the institutions as
a surrogate for specialized expertise in the treatment
of STSE. Cancer centres are distinguished from hos-
pitals, which are inpatient and surgical facilities; the
regional cancer centres in Ontario are chiefly ambu-
latory facilities which are the sole providers of radia-
tion oncology services, the major providers of medical
oncology services, and the chief foci of multidiscipli-
nary care encompassing surgical, radiation, and med-
ical  oncology  consultation  and  other  supportive
oncological disciplines.
‘Attendance at multidisciplinary cancer centre within 3 
months following diagnosis’
All permanent residents of  Ontario are  entitled to
consultation  and  treatment  without  charge.  Cases
attending  a  multidisciplinary  cancer  centre  within
3 months  of  diagnosis were  identified  from  OCR
records,  which  contain  the  date  of  enrollment  at
cancer centres.Soft tissue sarcoma of extremities 21
‘Region of residence’
The province of  Ontario was  divided into  regions
defined as the areas served by each multidisciplinary
cancer  centre.  The  STSE  cases  residing  in  each
census subdivision were  assigned  to  the  region  of
whichever  cancer  centre  was  most  frequently
attended by residents of the census subdivision.24,24
‘Initial treatment period’
Definitive surgery and adjuvant RT performed within
8  months  of  the  diagnosis  of  STSE  were  distin-
guished from those performed subsequently, in order
to identify initial treatment. The 8-month window
was selected in order to capture the cases that had a
preoperative or postoperative combination of surgery
and RT.
‘Definitive surgery for primary STSE’
A hierarchy of surgical procedures was established,
and only the highest ranking procedure during the first
8 months following diagnosis was selected as the defin-
itive surgery; amputation ranked highest, followed by
resection, followed by biopsy (lesser procedures are
not considered in the study).
Analysis of the processes of care
The case volumes of: (1) the hospital of first admis-
sion, and (2) the case volumes of the hospital where
the maximal surgery directed at the primary STSE
was performed, were computed. The proportion of
cases  of  STSE  attending  a  cancer  centre  within
3 months of diagnosis was computed. These propor-
tions  and  frequencies were  categorized  to  express
STSE case volume.
Rates of definitive surgery and adjuvant RT
Univariate and bivariate analysis of the rates of defin-
itive surgery and of adjuvant RT were performed. Chi-
square  tests  were  performed and  p  values  on  the
statistic were reported. Multivariate logistic regression
analyses were performed to assess: (1) the likelihood
of amputation as the definitive surgery, and (2) the
likelihood of adjuvant RT.
Outcome variables
Amputation at any time between diagnosis and last
contact or date of death was an outcome variable.
Amputation or resection directed at the primary ana-
tomic site of STSE at any time during follow-up after
definitive  surgery were considered to  be  surrogate
outcome measures of progressive or recurrent STSE
at the primary site. Death due to any cause was an
outcome.
Outcome analysis
Univariate and bivariate analyses using the life table
method were performed, to assess the time to ampu-
tation at any time (censoring all deaths), and overall
survival.  Multivariate  Cox  proportional  hazards
regression analysis was used to model: (1) the risk of
amputation conditional on survival (censoring cases
from the analysis at  the  time of  death  due to any
cause), and (2) the risk of death from any cause, con-
trolling  for  age,  gender,  histology,  region  of  resi-
dence, year of diagnosis, case volume of first hospital
and whether or not a case attended a cancer center
within 3 months after diagnosis.
Results
Description of study population
The OCR contains  records  of 1467 cases of STSE diag-
nosed  between 1 January 1987 and 31 December 1996.
ICD 171.2 (upper limb and shoulder girdle) com-
prised 23.6% of cases, ICD 171.3 (lower limb) 58.5%,
and ICD 171.6 (buttock and pelvic girdle) 17.9% of
the 1467 cases. Cases of STSE increased from 244 in
1987–1988 to 335 in 1995–1996 (Table 2).
Analysis of processes of care
STSE case volumes of hospitals
Patients were initially admitted at any one of 147 hos-
pitals;  135  hospitals  admitted  fewer  than  20  new
cases  of  STSE  during  the  10  years,  11  admitted
between 20 and 50 cases, and one hospital admitted
more than  50  cases. The percent of cases initially
admitted (1) at a hospital with < 20 cases of STSE
during 1987–1996 was 47.0%, (2) at a hospital with
20–50 cases 20.7%, and (3) at a hospital with > 50
cases 18.6%.  There was  no hospital record in the
CIHI electronic files for 13.7% of cases.
STSE case volumes of cancer centres
The percentage of  STSE cases attending a  cancer
centre was 56.7% within 90 days of diagnosis. Six
cancer centres received < 100 cases of STSE during
the study period; two centres received between 100
and 200 cases and one centre received > 200 cases.
Hospitals performing definitive surgery
Patients underwent definitive surgery at one of 139
hospitals. One hundred and thirty of these hospitals
performed definitive surgery on fewer than 20 cases
in total during the 10 years; seven performed defini-
tive surgery on between 20 and 50 cases during the
10 years; two performed definitive surgery on more
than 50 cases during the 10 years.
There was only a small shift of cases from hospitals
of  first  admission  with  smaller  case  volumes  to22 L. Paszat et al.
hospitals with larger case volumes for the maximal
surgical procedure: 45.5% had maximal surgery at a
hospital with < 20 cases (compared to 47% of first
admissions), 13.5%  at  a hospital with 20–50 cases
(compared to 18.6% of first admissions), and 27.3%
at a hospital with > 50 cases (compared to 13.7% of
first admissions). These are percentages of the entire
study population in each case; they do not sum to
100%,  or sum to  equal total  percentages, because
some cases had no admission, and some cases with an
admission had no surgery.
The  proportion  of  cases  undergoing  one  surgi-
cal procedure directed at the primary STSE within
8 months  after  diagnosis  was  43.4%;  23.2%
underwent two procedures; 7.8%  underwent three
or  more  procedures; 25.6%  did  not  undergo  any
procedure.
The proportion of cases undergoing definitive sur-
gery (Table 1) increased with (1) increasing STSE case
volume of the hospital of first admission (p<0.0001),
(2) increased among those registered at cancer centres
within 3 months of diagnosis (p < 0.0001), (3) varied
among regions of residence (p < 0.0001), but (4) did
not vary by year of diagnosis (p = 0.37).
The percentage of cases undergoing amputation:
(1) varied among the regions of Ontario (p = 0.05),
(2) decreased with increasing STSE case volume of
the  hospital  of  first  admission  (p = 0.04)  and
(3) decreased  with  attendance  at  a  cancer  centre
within 3 months of diagnosis (p = 0.08) (Table 1).
The percentage undergoing amputation did not vary
signficantly by year of diagnosis (p = 0.20).
Rates of adjuvant RT
The rates of RT increased with: (1) increasing STSE
case  load  of  the  hospital  of  first  admission
(p < 0.0001), and (2) increasing attendance rates at a
cancer  centre  within  3  months  of  diagnosis
(p < 0.0001) (Table 2). Variation among the regions
of Ontario was not significant (p=0.51).
Among  the  cases  with  amputation  as  definitive
surgery, 21/88 (23.9%) had a record of preoperative
adjuvant RT. Among cases with resection as defini-
tive surgery, 59/893 (6.6%) had a record of preoper-
ative adjuvant RT and 390/893 (43.7%) had a record
of postoperative adjuvant RT. Among cases having
had biopsy only, 45/110 (40.9%) had a record of RT
following biopsy. Among cases with no record of a
surgical procedure, 75/376 (20.0%) had a record of
RT directed at the primary site.
Multivariate analyses of treatment utilization
Multivariate  logistic  regression  analysis  (Table  3)
demonstrated that the odds ratio (OR) for amputa-
tion, adjusted for age, gender, histology, and anatomic
site of STSE was elevated in one region (adjusted
OR = 2.3; 95% CI (1.1, 7.4)) relative to the Toronto
region, but did not vary among the other regions, or
among years of diagnosis, STSE case volumes of the
hospital of first admission, or by attendance status at
a cancer centre within 3 months of diagnosis.
Multivariate logistic regression analysis of adjuvant
RT (Table 3) produced ORs for RT, adjusted for
age, gender, histology and anatomic subsites, which
were increased among those cases first admitted at
hospitals with the largest STSE case volume relative
to those with the smallest volume (adjusted OR=2.4;
95%  CI  (1.6,  3.7)),  and  decreased for  cases  not
attending a cancer centre within 3 months of diagno-
sis (adjusted OR = 0.2; 95% CI (0.1, 0.3)) relative to
those cases who attended. The odds ratios for RT did
not vary region of residence, or year of diagnosis.
Table 1. Description of definitive surgery and adjuvant RT, according to clinical variables
Variable Amputation Resection or biopsy No procedure Total RT directed at 
primary site
Age at diagnosis
17–29 7 (5.6%) 92 (73.0%) 27 (21.4%) 126 38 (30.2%)
30–49 29 (7.6%) 278(72.8%) 75 (19.6%) 382 167 (43.7%)
50–69 30 (5.9%) 349(68.7%) 129(25.4%) 508 211 (41.5%)
70–79 11 (3.9%) 190(67.4%) 81 (28.7%) 282 128 (45.4%)
> = 80 11 (6.5%) 94 (55.6%) 64 (37.9%) 169 46 (27.2%)
Gender
Female 36 (5.4%) 452(67.4%) 183(27.3%) 671 274 (40.8%)
Male 52 (3.5%) 551(69.2%) 193(24.3%) 796 316 (39.7%)
Histology
Malignant fibrous histiocytoma 16 (4.7%) 249(73.7%) 73 (21.6%) 338 169 (50.0%)
Fibrosarcoma 4 (8.2%) 31 (63.3%) 14 (28.6%) 49 24 (49.0%)
Liposarcoma 3 (1.0%) 248(84.4%) 43 (14.6%) 294 152 (51.7%)
Leiomyosarcoma 8 (4.7%) 103(59.9%) 61 (35.5%) 172 58 (33.7%) 
Rhabdomyosarcoma 3 (6.7%) 32 (71.1%) 10 (22.2%) 45 22 (48.9%)
Synovial sarcoma 15 (21.4%) 49 (70.0%) 6 (8.6%) 70 38 (54.3%)
Angiosarcoma 7 (11.3%) 35 (56.5%) 20 (32.3%) 62 20 (32.3%)
Sarcoma NOS 18 (12.8%) 84 (59.6%) 39 (27.7%) 141 52 (36.9%)
Other sarcoma 10 (5.7%) 110(62.9%) 55 (31.4%) 175 54 (30.9%)
Clinical diagnosis 4 (3.3%) 62 (51.2%) 55 (45.5%) 121 1  (0.8%)Soft tissue sarcoma of extremities 23
Outcomes analysis
Surrogate measures of uncontrolled or recurrent STSE 
at primary anatomic site
The electronic data do not contain information about
histological  confirmation  of  local  recurrence  of
STSE;  however,  records  of  surgery  subsequently
performed  after  the  initial  treatment  period  are
present for 14.2% of cases. Among the 893 cases with
surgical resection within 8 months following diagno-
sis, 18 (2.0%) subsequently underwent amputation
and 85 (9.5%) underwent another resection. Among
Table 2. Description of definitive surgery and adjuvant RT, according to process of care variables
Variable Amputation Resection or biopsy No procedure Total RT directed at 
primary site
Region
Ottawa 17 (11.8%) 91 (63.2%) 36 (25.0%) 144 55 (38.2%)
Toronto 34 (5.6%) 440 (71.8%) 139 (22.7%) 613 262 (42.7%)
Hamilton 8 (3.8%) 157 (73.7%) 48 (22.5%) 213 77 (36.2%)
Kingston 3 (4.0%) 55 (73.3%) 17 (22.7%) 75 33 (44.0%)
London 14 (7.8%) 128 (71.5%) 37 (20.7%) 179 82 (45.8%)
NW Ontario 4 (11.1%) 20 (55.6%) 12 (33.3%) 36 13 (36.1%)
Windsor 3 (4.8%) 45 (72.6%) 14 (22.6%) 62 29 (46.8%)
NE Ontario 5 (5.4%) 64 (68.8%) 24 (25.8%) 93 39 (41.9%)
Missing 52
Year of diagnosis
1987–1988 20 (8.2%) 163 (66.8%) 61 (25.0%) 244 85 (34.8%)
1989–1990 20 (7.7%) 166 (64.1%) 73 (28.2%) 259 94 (36.3%)
1991–1992 17 (5.7%) 194 (65.5%) 85 (28.7%) 296 116 (39.2%)
1993–1994 15 (4.5%) 237 (71.2%) 81 (24.3%) 333 145 (43.5%)
1995–1996 16 (4.8%) 243 (72.5%) 76 (22.7%) 335 150 (44.8%)
Case volume of first hospital
< 20 cases 44 (6.4%) 528 (76.6%) 117 (17.0%) 689 275 (40.1%)
20–50 cases 30 (9.9%) 230 (75.7%) 44 (14.5%) 304 150 (49.3%)
> 50 cases 14 (5.1%) 245 (89.7%) 14 (5.2%) 273 165 (60.8%)
No admission 201
Registration at centre > = 3 months
Yes 58 (65.9%) 634 (63.2%) 140 (25.6%) 832 542 (65.1%)
No 30 (34.1%) 369 (36.8%) 236 (74.4%) 635 48 (7.6%)
Table 3. Odds ratios for amputation as definitive surgery, and odds ratios for adjuvant RT, by process of care variables, 
simultaneously adjusted for clinical variables
Variable Odds ratio for amputation as 
definitive surgery
Odds ratio for RT directed at 
the primary site
Region
Ottawa 2.3 (1.2, 4.5) 0.9 (0.5, 1.5)
Toronto 1.0 1.0
Hamilton 0.6 (0.3, 1.3) 0.7 (0.4, 1.0)
Kingston 0.5 (0.1, 1.8) 1.4 (0.7, 2.8)
London 1.5 (0.7, 3.0) 0.9 (0.6, 1.5)
NW Ontario 1.1 (0.4, 4.3) 0.7 (0.3, 1.9)
Windsor 0.9 (0.3, 3.4) 1.2 (0.6, 2.6)
NE Ontario 0.7 (0.2, 2.2) 1.1 (0.6, 2.0)
Year of diagnosis
1987–1988 1.7 (0.8, 3.5) 0.7 (0.5, 1.1)
1989–1990 1.8 (0.9, 3.7) 0.7 (0.5, 1.0)
1991–1992 1.3 (0.6, 2.6) 0.7 (0.5, 1.0)
1993–1994 0.9 (0.4, 1.9) 1.0 (0.7, 1.3)
1995–1996 1.0 1.0
Case volume of first hospital
< 20 cases 1.0 1.0
20–50 cases 1.5 (0.9, 2.6) 1.1 (0.9, 1.9)
> = 50 cases 0.7 (0.4, 1.7) 2.4 (1.6, 3.7)
Registration at cancer centre within 3 months
Yes 1.0 1.0
No 1.5 (0.7, 3.0) 0.2 (0.1, 0.3)24 L. Paszat et al.
the  110  cases  with  biopsy  within  8  months,  four
(3.6%)  cases  subsequently  underwent  amputation
and five (4.5%) cases resection. Among the 376 cases
without  a  record  of  surgical  procedure  within  8
months  following  diagnosis,  7/376  (1.8%)  subse-
quently underwent amputation, and 39/376 (10.4%)
resection.
Analysis of time to amputation
Analysis of time to amputation (at any time between
the date of diagnosis and last follow-up) by the life
table method, censoring all deaths, demonstrated a
difference among the anatomic subsites (log-rank test
p = 0.002; Wilcoxon test p=0.003).
Multivariate  analysis  of  the  time to  amputation,
using Cox proportional hazards regression (Table 4),
censoring deaths due to any cause demonstrated that
the relative risk (RR) for amputation, adjusted for
age,  gender,  histology  and  anatomic  subsites, was
3.48 (95% CI (1.63, 7.46)) for those not attending a
cancer  centre  within  3  months,  but  did  not  vary
among the regions of residence, years of diagnosis, or
hospital categories according to STSE case volume.
Survival analysis
Overall survival for the entire population was 64.0%
at 5 years; cause-specific survival was 80.0%. Over-
all survival did not vary by region of residence, or
case volume of first hospital, but varied by year of
diagnosis  and  by  attendance  status  at  a  regional
cancer centre.
Multivariate Cox proportional hazards regression
analysis of overall survival demonstrated a relative risk
for death due to any cause, adjusted for age, gender,
histology, and anatomic subsite, which was elevated
(1) for all years of diagnosis relative to 1995–1996
(Table 4), and (2) for cases not attending a cancer
centre within 3 months of diagnosis (RR = 1.4; 95%
CI (1.1, 1.7). The adjusted RR for death did not vary
among the regions of Ontario relative to Toronto, or
according to the STSE case volume of the hospitals
of first admission.
Discussion
STSE case volumes of hospitals and cancer centres
For 45% of cases, definitive surgery was performed at
a hospital treating < = 2 new cases per year. Only
13.6% of cases admitted to low case volume hospitals
were referred to larger case volume hospitals for sur-
gery. A total of 9.4% of cases residing in regions with
low case volume cancer centres was referred to cen-
tres with larger case volume. The percentage of all
cases of STSE attending a multidisciplinary cancer
centre within 3 months of diagnosis was 56.7%. Most
cancer centres treated fewer than 100 new cases of
STSE during the study period.
These observations indicate that recommendations
in the clinical literature for expert multidiscplinary
care are not implemented for many cases.1–5,8–10 We
hypothesize  that  many  patients  may  be  receiving
treatment for STSE at institutions with insufficient
case  volumes  to  develop  or  maintain  specialized
Table 4. The relative risk of amputation at any time, and the relative risk of death, by process of care variables, simultaneously 
adjusted for clinical variables
Variable Relative risk of amputation at 
any time
Relative risk of death due to 
any cause
Region of residence
Ottawa 1.7 (0.7, 4.2) 0.7 (0.5, 1.0)
Toronto 1.0 1.0
Hamilton 0.9 (0.3, 2.2) 0.8 (0.6, 1.0)
Kingston 0.5 (0.1, 2.5) 0.7 (0.5, 1.2)
London 1.4 (0.6, 3.6) 0.7 (0.5, 1.0)
NW Ontario 0.7 (0.1, 6.0) 1.6 (1.0, 2.6)
Windsor 1.5 (0.4, 5.7) 0.9 (0.6, 1.4)
NE Ontario 0.7 (0.2, 2.4) 0.8 (0.5, 1.2)
Year of diagnosis
1987–1988 2.5 (0.7, 9.27) 1.9 (1.3, 2.7)
1989–1990 3.6 (1.0, 13.1) 1.6 (1.1, 2.4)
1991–1992 2.0 (0.5, 7.3) 1.7 (1.2, 2.5)
1993–1994 1.1 (0.3, 4.8) 1.7 (1.1, 2.5)
1995–1996 1.0 1.0
Case volume of first hospital
< 20 cases 1.00 1.00
20–50 cases 1.1 (0.6, 2.7) 1.1 (0.8, 1.3)
> 50 cases 0.7 (0.3, 1.7) 0.8 (0.6, 1.1)
Registration at cancer centre within 3 months
Yes 1.0 1.0
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expertise. We hypothesize that many patients treated
only in low case volume hospitals and cancer centres
do  not  receive  expert  multidisciplinary  care  for
STSE.
Cases without record of surgery or RT
Cases without record of surgery or adjuvant RT likely
include: (1) cases diagnosed with detectable meta-
static  disease,  (2)  cases  whose  comorbid  illnesses
prevented definitive treatment or whose prognoses
from comorbid illness rendered treatment of STSE
unnecessary, (3) cases who indeed received surgery
and/or RT directed at the primary site of STSE but
who lacked an electronic record of the procedures,
and (4) cases of very small Stage Ia STSE who under-
went a minor excision in a doctor’s office and had no
hospital procedure and did not require RT.
Surrogate outcome measures of local recurrence of 
primary STSE
The surrogate outcome measure of local recurrence
of STSE following primary treatment is the percent-
age  of  cases  initially  treated  by  surgical  resection
subsequently  undergoing  amputations  or  further
resections. A total  of 2.0%  underwent amputation
and  9.5%  underwent  further  resection;  this  com-
bined percentage (11.5%) is higher than the rate of
local recurrence reported in the best single-institution
cases  series  studies.15  We  recall  that  Gustafson
reported  local  recurrence  rates  2.4  times  higher
among  cases  of  STSE  not  referred to  specialized
sarcoma units.3,4 Population-based STSE outcomes
are not optimized in most jurisdictions from which
they have been reported.
Constraints on interpretation of these administrative 
databases
Interpretation of these results is constrained by the
absence of information on stage including grade of
STSE, physician characteristics, diagnostic imaging,
pathology reporting, adjuvant chemotherapy, or local
recurrence or metastasis  of  STSE.  Because of  the
absent covariates, it is not possible to compare the
care received by these cases to the practice guidelines
of the Society of Surgical Oncology6 or the National
Comprehensive Care Network.7
Treatment selection biases obviously confound the
examination  of  associations  between  processes  of
care  and  outcomes;  therefore,  we  have  avoided
making outcome comparisons on the basis of treat-
ment for STSE. Overall survival was positively asso-
ciated with attendance at  a cancer centre within 3
months of diagnosis, but not with region of residence
or with case volume of the hospital; this may reflect a
referral bias if patients with more advanced STSE or
more serious comorbid illness are less likely to be
referred to a cancer centre. It is not possible to assess
survival benefit from cancer centre attendance with
the available covariates.
Importance of population-based study of processes and 
outcomes of care
The study of the processes and outcomes of care on
a population basis is important, despite the absence
of  certain  variables  from  electronic  databases.
Patients enrolled within clinical trials for their treat-
ment  often  have  better  outcomes  than  patients
treated outside of clinical trials. They are rigorously
selected  to  be  comparable,  and  their  physicians,
treating  institutions,  and  treatment  processes  are
subject  to  stringent  guidelines.26  The  treatment
benefits  seen in  randomized clinical  trials  may  be
diminished when the treatment is implemented in the
general population, because the spectrum of patients
treated will be broader, and there will be a broader
range  of  treatment  processes  and  physician  and
institutional  expertise  outside  of  the  context  of  a
randomized clinical trial.27,28
Population-based studies are necessary to  reveal
the processes of care in the general population and to
determine  aspects  of  the  processes  that  require
improvement.  Such  studies  will  never  be  able  to
adjust for unknown treatment selection variables or
stage, but are useful for the generation of hypotheses
for further study.
Sources of problems in the processes of care for STSE
Problems with the processes of care for STSE may
relate to practitioner and/or institutional inexperience
and to failure to disseminate knowledge and guide-
lines about the care of STSE. The Society for Surgi-
cal Oncology has published consensus-based surgical
guidelines,6  and  the  National  Comprehensive
Cancer  Network  has  published  consensus-based
guidelines for a range of diagnostic and therapeutic
scenarios in soft tissue sarcoma.7
Conclusion
Multivariate time to failure analyses have shown that
cases  not  attending  any  cancer  centre  within  3
months following diagnosis have a higher relative risk
of amputation at any time, and a higher relative risk
of death from any cause.
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